ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2026-01-29. Here’s what investors need to know before the announcement.
Analysts estimate that ResMed will report an earnings per share (EPS) of $2.71.
The announcement from ResMed is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It’s worth noting for new investors that guidance can be a key determinant of stock price movements.
Performance in Previous Earnings
During the last quarter, the company reported an EPS beat by $0.05, leading to a 2.13% drop in the share price on the subsequent day.
Here’s a look at ResMed’s past performance and the resulting price change:
| Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|
| EPS Estimate | 2.50 | 2.47 | 2.36 | 2.31 |
| EPS Actual | 2.55 | 2.55 | 2.37 | 2.43 |
| Price Change % | -2.00 | 3.00 | 10.00 | -8.00 |
Stock Performance
Shares of ResMed were trading at $255.5 as of January 27. Over the last 52-week period, shares are down 0.25%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
Insights Shared by Analysts on ResMed
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding ResMed.
A total of 6 analyst ratings have been received for ResMed, with the consensus rating being Outperform. The average one-year price target stands at $289.5, suggesting a potential 13.31% upside.
Peer Ratings Overview
In this comparison, we explore the analyst ratings and average …